Apart from cholinesterase inhibition, which remains the current effective therapeutic option for symptomatic relief, some other activities can be inserted into the MTDLs to design and produce an extensive variety of possible dual- and multi-acting anti-AD compounds [119,120,121]. The gene discussed is BCHE; the disease is Alzheimer disease.